https://www.selleckchem.com/products/hrs-4642.html
02) and overall survival with [ F]FMISO TNR (p = 0.003) and [ F]FDG TGV (p = 0.02) was observed. Serum levels of osteopontin, but not VEGF, correlated with [ F] FMISO and [ F]FDG PET scan parameters. [ F]FMISO PET uptake in metastatic colorectal cancer significantly correlates with glycolytic metabolism and is predictive of progression-free and overall survival. These findings have implications for the assessment and treatment of metastatic colorectal cancer patients with novel therapies which affect tumour angiogenesis and hypoxia. [1